p16 expression in relation to human papillomavirus in anogenital lesions

Human Pathology

Volumn 37, Issue 5, 2006, Pages 513-519

  Samama, Brigitte ^a,b,c   Lipsker, Dan ^c   Boehm, Nelly ^a,b,c  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Anogenital lesions; HPV; Immunohistochemistry; In situ hybridization; p16

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROTEIN P16;

ARTICLE; CONTROLLED STUDY; EPISOME; FEMALE; GENITAL SYSTEM DISEASE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; VIRUS DETECTION; WART VIRUS;

ANUS DISEASES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 33646131602     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.01.001     Document Type: Article

References (35)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. von Knebel Doeberitz M. New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38 (2002) 2229-2242
3. Khleif S.N., DeGregori J., Yee C.L., et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 93 (1996) 4350-4354
4. Sano T., Oyama T., Kashiwabara K., Fukuda T., and Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153 (1998) 1741-1748
5. Klaes R., Friedrich T., Spitkovsky D., et al. Overexpression of p16INK4 as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92 (2001) 276-284
6. Klaes R., Benner A., Friedrich T., et al. P16INK4 immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 26 (2002) 1389-1399
7. Riethdorf S., Neffen E.F., Cviko A., Loning T., Crum C.P., and Riethdorf L. P16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol 35 (2004) 1477-1483
8. Nindl I., Meyer T., Schmook T., et al. Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer. Dermatol Surg 30 (2004) 409-414
9. Samama B., Plas-Roser S., Schaeffer C., Chateau D., Fabre M., and Boehm N. HPV DNA detection by in situ hybridization with catalyzed signal amplification on thin-layer cervical smears. J Histochem Cytochem 50 (2002) 1417-1420
10. Ferreux E., Lont A.P., Horenblas S., et al. Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 201 (2003) 109-118
11. Cooper K., Herrington C.S., Stickland J.E., Evans M.F., and McGee J.O. Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridisation. J Clin Pathol 44 (1991) 990-996
12. Unger E.R., Vernon S.D., Thoms W.W., et al. Human papillomavirus and disease-free survival in FIGO stage Ib cervical cancer. J Infect Dis 172 (1995) 1184-1190
13. Fetsch P.A., Cormier J., and Hijazi Y.M. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J Immunother 20 (1997) 60-64
14. Milde-Langosch K., Riethdorf S., Kraus-Poppinghaus A., Riethdorf L., and Loning T. Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchows Arch 439 (2001) 55-61
15. Klussmann J.P., Gultekin E., Weissenborn S.J., et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162 (2003) 747-753
16. Murphy N., Ring M., Killalea A.G., et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 56 (2003) 56-63
17. Geradts J., Kratzke R.A., Niehans G.A., and Lincoln C.E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55 (1995) 6006-6011
18. Tsuda H., Hashiguchi Y., Nishimura S., Kawamura N., Inoue T., and Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 91 (2003) 476-485
19. Zhang H., and Rosdahl I. Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells. Int J Oncol 24 (2004) 331-335
20. Keller-Melchior R., Schmidt R., and Piepkorn M. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J Invest Dermatol 110 (1998) 932-938
21. Ghiorzo P., Villagio B., Sementa A.R., et al. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum Pathol 35 (2004) 25-33
22. Masumoto N., Fujii T., Ishikawa M., et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 34 (2003) 778-783
23. Zur Hausen H. Oncogenic DNA viruses. Oncogene 20 (2001) 7820-7823
24. Dyson N., Howley P.M., Munger K., and Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243 (1989) 934-937
25. Munger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 89 (2002) 213-228
26. Fregonesi P.A.G., Baretto D., Duarte R.A., Neto C.B., Brancini de Oliveira M.R., and Soares C.P. P16INK4 immunohistochemical overexpression in premalignant and malignant oral lesions infected with human papillomavirus. J Histochem Cytochem 51 (2003) 1291-1297
27. Hodges A., and Smoller B.R. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol 15 (2002) 1121-1125
28. Nakamura S., and Nishioka K. Enhanced expression of p16 in seborrheic keratosis; a lesion of accumulated senescent epidermal cells in G1 arrest. Br J Dermatol 149 (2003) 560-565
29. Elias A.N., Barr R.J., and Nanda V.S. P16 expression in psoriatic lesions following therapy with propylthiouracil, an antithyroid thioureylene. Int J Dermatol 43 (2004) 889-892
30. Pavey S., Conroy S., Russell T., and Gabrielli B. Ultraviolet radiation induces p16CDKN2A expression in human skin. Cancer Res 59 (1999) 4185-4189
31. Simonetti O., Lucarini G., Bernardini M.L., Simoncini C., Biagini G., and Offidani A. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol 150 (2004) 940-948
32. Nakao Y., Yang X., Yokoyama M., et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 75 (1997) 1410-1416
33. Schlecht N.F., Platt R.W., Duarte-Franco E., et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95 (2003) 1336-1343
34. Kanao H., Enomoto T., Ueda Y., et al. Correlation between p14 (ARF)/p16 (INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett 213 (2004) 31-37
35. Schorge J.O., Lea J.S., Elias K.J., et al. P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 190 (2004) 668-673